Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2024 1
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean samanidou e (2 results)?
Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial.
Chataway J, Williams T, Blackstone J, John N, Braisher M, De Angelis F, Bianchi A, Calvi A, Doshi A, Apap Mangion S, Wade C, Bordea E, Merry R, Barton G, Lyle D, Jarman E, Mahad D, Shehu A, Arun T, McDonnell G, Geraldes R, Craner M, Hillier C, Ganesalingam J, Fisniku L, Hobart J, Spilker C, Robertson NP, Kalra S, Pluchino S, Harikrishnan S, Mattoscio M, Harrower T, Young C, Lee M, Chhetri SK, Ahmed F, Rog D, Silber E, Gallagher P, Duddy M, Straukiene A, Nicholas R, Rice C, Tebbs S, Hawton A, Hunter R, Giovannoni G, Ciccarelli O, Beveridge J, Nixon S, Thompson AJ, Greenwood J, Pearson OR, Evangelou N, Sharrack B, Galea I, Gray E, Pavitt S, Chandran S, Ford HL, Frost C, Nicholas JM; MS-STAT2 Investigators. Chataway J, et al. Lancet. 2025 Oct 11;406(10512):1611-1624. doi: 10.1016/S0140-6736(25)01039-6. Epub 2025 Oct 1. Lancet. 2025. PMID: 41045938 Free article. Clinical Trial.
Single-centre, prospective cohort to predict optimal individualised treatment response in multiple sclerosis (POINT-MS): a cohort profile.
Christensen R, Cruciani A, Al-Araji S, Bianchi A, Chard D, Fourali S, Hamed W, Hammam A, He A, Kanber B, Maccarrone D, Moccia M, Mohamud S, Nistri R, Passalis A, Pozzilli V, Prados Carrasco F, Samdanidou E, Song J, Wingrove J, Yam C, Yiannakas M, Thompson AJ, Toosy A, Hacohen Y, Barkhof F, Ciccarelli O; POINT-MS Group. Christensen R, et al. Among authors: samdanidou e. BMJ Open. 2025 Sep 25;15(9):e103440. doi: 10.1136/bmjopen-2025-103440. BMJ Open. 2025. PMID: 40998429 Free PMC article.
Response to letter to the editor: 'Investigating the complementary value of OCT to MRI in cognitive impairment in relapsing-remitting multiple sclerosis'.
Christensen R, Jolly A, Yam C, Yiannakas MC, Toosy AT, Pitteri M, He A, Nistri R, Mohamud S, Samdanidou E, Thompson AJ, Ciccarelli O. Christensen R, et al. Among authors: samdanidou e. Mult Scler. 2025 Jul;31(8):1016-1018. doi: 10.1177/13524585251329787. Epub 2025 Apr 12. Mult Scler. 2025. PMID: 40219831 No abstract available.